Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Free Cash Flow (2016 - 2025)

Adma Biologics' Free Cash Flow history spans 13 years, with the latest figure at $34.6 million for Q4 2025.

  • For Q4 2025, Free Cash Flow fell 27.19% year-over-year to $34.6 million; the TTM value through Dec 2025 reached $27.8 million, down 74.81%, while the annual FY2025 figure was $27.8 million, 74.81% down from the prior year.
  • Free Cash Flow reached $34.6 million in Q4 2025 per ADMA's latest filing, up from -$1.1 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $47.5 million in Q4 2024 to a low of -$37.1 million in Q4 2021.
  • Average Free Cash Flow over 5 years is -$2.9 million, with a median of -$9.0 million recorded in 2022.
  • Peak YoY movement for Free Cash Flow: skyrocketed 728.77% in 2024, then crashed 433.98% in 2025.
  • A 5-year view of Free Cash Flow shows it stood at -$37.1 million in 2021, then soared by 70.04% to -$11.1 million in 2022, then surged by 247.38% to $16.4 million in 2023, then soared by 189.38% to $47.5 million in 2024, then fell by 27.19% to $34.6 million in 2025.
  • Per Business Quant, the three most recent readings for ADMA's Free Cash Flow are $34.6 million (Q4 2025), -$1.1 million (Q3 2025), and $18.7 million (Q2 2025).